We investigated the pretreatment effects of low-dose luseogliflozin, an SGLT2 inhibitor, in a mouse model of ischemic stroke and assessed the expression and function of SGLT2 in the brain. This evidence concerns the gene SLC5A2 and ischemic stroke.